Trial Profile
Nimotuzumab for the treatment of castration-resistant prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jan 2011
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Mitoxantrone; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jan 2011 New trial record